Companies that own Staidson
Huatai Securities (Shanghai) Asset Management Co., Ltd.
9,382,600
2%
-2,127,958
7.9%
03/31/2018
Suzhou Trust Co., Ltd.
7,060,000
1.51%
-4,440,000
3.61%
05/11/2018
China Investment Corp. (Investment Management)
2,437,253
0.52%
0
0.01%
03/31/2018
Everbright Pramerica Fund Management Co., Ltd.
1,492,022
0.32%
1,492,022
0.11%
03/31/2018
Bosera Asset Management Co., Ltd.
831,342
0.18%
16,923
0.01%
12/31/2017
The Vanguard Group, Inc.
831,119
0.18%
0
0%
07/31/2018
Galaxy Asset Management Co., Ltd.
350,800
0.08%
350,800
0.03%
12/31/2017
China Merchants Fund Management Co., Ltd.
333,835
0.07%
13,300
0.01%
12/31/2017
E Fund Management Co., Ltd.
116,488
0.03%
-28,800
0%
12/31/2017
Rongtong Fund Management Co., Ltd.
34,900
0.01%
-72,600
0%
12/31/2017
| Address |
36 Jinghai 2nd Road
Beijing Beijing 100176
China
|
|
Employees
|
- |
| Website |
http://www.staidson.com |
| Updated |
07/08/2019 |
| Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research, development, production, and sale of independent intellectual property innovation drugs. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin. The company was founded on August 16, 2002 and is headquartered in Beijing, China. |
